Company intelligence / Profile preview

RetroVirox

San Diego, California, United Statesretrovirox.com ↗

Ownership: Private
Employees: ~25
Development stage: Other

Overview

RetroVirox develops novel small-molecule immunomodulators targeting HIV eradication and cancer therapy. It also provides extensive antiviral assay services to biotech/pharma clients worldwide. Its pipeline includes preclinical candidates for HIV cure strategies using new mechanisms of action that block viral entry. The company has received over $5 million in NIH SBIR grants to support its research efforts.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculeImmunomodulatorBiologic
Industry: Biotech

Drug pipeline

1 asset

RetroVirox HIV Nef inhibitors

Preclinical

Partnerships

Not specifically listed by name; collaborates with hundreds of biotech/pharma companies globally through fee-for-service or FTE contracts for antiviral testing.

Beyond the preview

Go deeper on RetroVirox.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RetroVirox.

Explore the full profile